Pfizer Interest In Biosimilars Appears To Decline As Firm Ceases To Split Out Segment

Launch Of Humira Challenger In 2023 May Rejuvenate The Area

 
• By Chloe Kent
  
Pfizer logo next to syringe
Pfizer's biosimilar business appears to be on the backburner for the time being • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products